Drugs / LEO 22811
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01211964 | Sep → Dec 2010 | — | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00833872 | Jan → Oct 2009 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01116895 Comparator | May 2010 → Mar 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEO 22811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01116895 ↗ |
| Route | Oral | “Oral administration of solution and tablet.” NCT01211964 ↗ |